Abstract Preclinical research in murine models as well as subsequent clinical trials have concordantly revealed a high protective potential of antiviral CD8 T cells, of donorderived ex vivo memory CD8 T cells in particular, in the immunotherapy of cytomegalovirus (CMV) infection in immunocompromised recipients. Although it is generally held view that the observed beneficial effect of the transferred cells is viral epitope-specific, involving the recognition of MHC class-I presented peptides by cognate T cell receptors, this assumption awaits formal proof, at least with regard to the in vivo function of the CD8 T cells. This question is particularly evident for CMV, since the function of viral immune evasion proteins interferes with the MHC class-I pathway of peptide presentation. Alternatively, therefore, one has to consider the possibility that the requirement for epitope recognition may be bypassed by other ligand-receptor interactions between CD8 T cells and infected cells, which may trigger the signaling for effector functions. Clearly, such a mechanism might explain why CD8 T cells are so efficient in controlling CMV infection despite the expression of viral immune evasion proteins. Here we provide direct evidence for epitope-specificity of antiviral protection by employing a recombinant murine CMV (mCMV), namely the mutant virus mCMV-IE1-L176A, in which an immunodominant viral epitope of the regulatory immediate-early protein IE1 is functionally deleted by a point mutation replacing leucine with alanine at the C-terminal MHC anchor position of the antigenic peptide.
Introduction and rationale of the question addressed
Immunotherapy by adoptive transfer of donor-derived CD8 T cells is a promising option to avoid cytomegalovirus disease in immunocompromised recipients of hematopoietic stem cell transplantation (HSCT), both in the murine model [1, 2] and upon clinical application [3, 4] (see the accompanying review article by Holtappels et al. in this issue of MMI). Notably, in a preemptive therapy regimen tested in the BALB/c mouse model-a regimen that involves HSCT and adoptive T cell transfer on the day of murine CMV (mCMV) infection of immunocompromised recipients-as few as 400 IE1 epitope-specific, T cell receptor (TCR)-sorted memory CD8 T cells (CD8-T M ) derived from latently infected and thus CMV-immune donors inhibited the infection of the recipients' spleen by 3 log 10 infectious units compared to a ''no therapy'' control group. Moreover, 10 4 of these cells proved to be curative in that they completely prevented viral histopathology and organ disease with no detectable side effect of immunopathology [1] (see also the accompanying review article by Holtappels et al. 
in this issue of MMI).
Such an impressive dose-effectiveness of CD8 T cell transfer is somewhat surprising in view of the fact that CMV-infected cells express virus-encoded glycoproteins, so called immunoevasins, that are specifically dedicated to interfere with the MHC class-I pathway of antigenic peptide presentation to CD8 T cells (for a review, see [5] ). As shown for cells infected with wild-type mCMV (mCMV-WT), the concerted action of immunoevasins m04/gp34, m06/gp48, and m152/gp40 completely prevents lysis of infected cells by a large array of CTLs differing in MHCrestriction and in the epitopes recognized [6, 7] , although CTL specific for the D d -restricted m164-epitope represent a reported exception [8] . In principle, these findings also apply to the triggering of a second effector function of CD8 T cells, namely the secretion of interferon (IFN)-c as measured in an ELISpot assay. Unlike the lysis of infected target cells, the ELISpot assay gives an estimate of the numbers of CD8 T cells that are capable of detecting presented peptide and that receive sufficient signaling required for IFN-c synthesis and secretion. In the ELISpot assay the inhibition by the concerted action of the three immunoevasins was less complete compared to the cytolysis assay in that a small proportion of CD8 T cells, most likely those with the highest functional avidity and TCR affinity, were sensitized by cells infected with mCMV-WT [7] . Nevertheless, there is consent between our group and Ann Hill's group (see the contribution by Doom and Hill in this issue of MMI) that the inhibition exerted by the concerted action of all three immunoevasins is stronger than for any of the immunoevasins expressed alone or for any combination of two of them. Thus, there remains an obvious discrepancy between the almost complete inhibition of antigen presentation observed in vitro for a variety of cell types, including fibroblasts, macrophages, dendritic cells, and the strong protective function of CD8 T cells against mCMV-WT infection in vivo. Apparently, this discrepancy not only applies to adoptive CD8 T cell transfer, but may also explain the very limited impact of immunoevasin gene deletion in recombinant virus mCMVDm04 + m06 + m152 on the control of infection in immunocompetent mice [9] (see also the contribution by Doom and Hill in this issue of MMI). Clearly, if mCMV-WT is already almost completely controlled, how can we expect any significant further improvement by the deletion of the immune evasion genes?
Another striking finding revealed by the immunotherapy studies was the apparent irrelevance of the type of epitope; essentially all CTL lines (CTLL) protected in adoptive transfer assays regardless of the immunodominance status IgG1-iso [1] for more details of the assay and the calculations). b (right panel) IFN-c ELISpot assay with the IE1-CTLL as responder cells and with MEF as stimulator cells infected at a multiplicity of 4 with BACderived mCMV-WT.BAC or the mutant viruses indicated. n.i. Notinfected MEF, UV UV-light inactivated mCMV-WT.BAC of the respective antigenic peptide (for reviews, see [10] and the accompanying article by Holtappels et al. in this issue of MMI). We therefore began to wonder if the observed protection was based on TCR-mediated recognition of MHC class-I presented antigenic peptide at all. Actually, it is known that at least activated CD8 T cells express NKG2D, better known as an activating natural killer (NK) cell receptor interacting with cellular ligands of the RAE-1 family, as well as with H60 and MULT-1. Furthermore, mCMV-infected cells express the virus-encoded ligand m157 of the activating NK cell receptor Ly49H that is expressed in C57BL/6 mice (for reviews, see [11] and the accompanying article by Lenac in this issue of MMI). Although the latter example applies to NK cell function, still unknown ligand-receptor interactions between infected cells and activated T cells might likewise exist, which could possibly account for a TCR-and epitope-independent triggering of protective effector functions. Such a TCRbypassing induction of effector function would even be specific for mCMV-infected cells in the case that the putative ligand is virus-encoded or at least selectively expressed.
To our knowledge, epitope-specificity of the CD8 T cell-mediated protection against CMV has never been proven in a formal scientific sense. Here we report on our approach to solve this problem.
Results

NKG2D expression and target cell recognition by an IE1-epitope specific CTLL
As explained in detail in the accompanying review by Holtappels et al. (this issue of MMI), epitope-specific CD8 T cells for adoptive cell transfer can either be generated from a polyclonal and polyspecific pool of CD8-T M by selection through repeated restimulation with the MHCpresented cognate antigenic peptide, resulting in an epitope-specific CTLL, or can be directly purified from the pool of CD8-T M by TCR-based epitope-specific cell sorting making use of MHC-peptide multimers as TCR ligands.
With the aim to realize the first strategy, we generated a CTLL specific for the L d -restricted IE1 peptide 168-YP-HFMPTNL-176 ( Fig. 1) . After as few as three rounds of in vitro restimulation of CD8-T M , the resulting short-term CTLL proved to be still polyclonal-as indicated by a broad TCR-b chain usage (Fig. 1a , top)-but already epitope-specific, since virtually all cells were stained by an MHC-IE1-peptide pentamer. Notably, most of the cells coexpressed NKG2D (Fig. 1a, bottom) . It should be noted that all cells also still expressed the co-receptor molecule CD8 (data not shown) [1] , which is important for the avidity of target cell recognition.
A polyclonal CTLL usually consists of individual cells differing in TCR affinity and functional avidity. The range of functional avidities represented in the particular IE1-specific CTLL studied herein, was assessed in an IFNc secretion-based ELISpot assay using L -
Expression of MHC class-I molecules and of NKG2D ligand RAE-1 by infected MEF. (Left column) Two-color cytofluorometric analysis of the expression of the ER-resident viral glycoprotein m164/ gp36.5 (ordinate log fluorescence scale; Alexa Fluor 488), identifying infected cells, and the MHC class-I molecule L d (abscissa log fluorescence scale; PE) performed as described in greater detail previously [7] . Shown are dot plots with 2,000 cells displayed. (Right column) Corresponding analysis, except that abscissa PE fluorescence represents the expression of RAE-1 measured by using PE-conjugated rat anti-mouse RAE-1c antibody (CX1, Pharmingen). MEF were infected at a multiplicity of 4 with the viruses indicated. n.i. Notinfected MEF, UV UV-light inactivated mCMV-WT.BAC as stimulator cells exogenously loaded with synthetic IE1 peptide in graded concentrations (Fig. 1b, left panel) . Whereas high-avidity cells in the CTLL population recognized presented IE1 epitope at a peptide concentration of 10 -10 M, low avidity cells became sensitized only at 10 -8 M. Higher concentrations did not recruit more CTL for recognition, which implies that all cells that are capable of responding were stimulated.
The recognition of endogenously processed and presented IE1 peptide by the so characterized CTLL was tested with MEF as stimulator cells (Fig. 1b, right panel) . Absence of CTL sensitization by uninfected MEF (n.i. not infected) verified the virus-specificity of the CTLL, which implies that cross-recognition of cellular peptides by IE1-specific TCRs played no role. Absence of sensitization by MEF exposed to UV light-inactivated virus showed that viral gene expression is required, thus excluding a possible recognition of virion protein-derived peptides [12, 13] as well as of cellular peptides induced by the signaling and the resulting global change of the cellular transcriptome that is associated with the viral entry process (for reviews see [14, 15] ). In accordance with all what we have learnt about immunoevasins encoded by mCMV (for reviews see [5, 10, 16, 17] , as well as the article by Doom and Hill in this issue of MMI), MEF infected with mCMV-WT.BAC stimulated only a minor fraction of the IE1-specific CTL in this T cell line, most likely those with the highest avidity. Absence of viral immunoevasins m04/gp34 and m06/gp48 in MEF infected with the respective deletion mutant mCMVDm04 + 06 improved peptide presentation and thus recruited also CTL with somewhat lower avidity. Stimulation of all cells that are capable of responding (recall Fig. 1b, left panel) required the additional deletion of the immunoevasin m152/gp40 in MEF infected with the respective deletion mutant mCMV-Dm04 + 06 + 152 (Fig. 1b, right panel) .
RAE-1 ligands of NKG2D do not mediate the sensitization of an IE1-specific CTLL So far so good, but do we really have definite proof for TCR-mediated IE1-epitope specificity of the CTL sensitization? Alternatively, one might have speculated that other receptor-ligand pairs formed between the CD8 T cells and infected stimulator cells might account for triggering IFN-c synthesis in the activated CD8 T cells also in a TCRindependent manner, with NKG2D-RAE-1 interaction being a candidate. Clearly, such a mechanism can hardly explain the peptide-dose dependence of the recognition of uninfected cells exogenously loaded with antigenic peptide (see above), but the situation is less obvious for infected cells.
As shown above, cells of the IE1-specific CTLL express NKG2D. For interaction with RAE-family members to occur, namely RAE-1a, b, and c in the case of BALB/c mice [18] , these molecules must be expressed by the stimulator or target cells. It is known, however, that the immunoevasin m152/gp40 simultaneously down-regulates MHC class-I and RAE-1 cell surface expression (for a review, see [11] ), a finding reproduced by us in the [27] . For anulling antigenicity, the C-terminal anchor residue leucin is replaced with alanine (L176A) by introducing the codon mutation CTA ? GCA into the BAC-cloned mCMV genome. Revertants A176L and A176L* were generated by replacing alanine with leucin by means of codon mutations GCA ? CTA and GCA ? CTT, respectively [21] . Mutations are marked in red. Reproduced from Ref. [22] with permission by Caister Academic Press experiment shown in Fig. 2 . As in our experience cultures of infected MEF always contain cells that are refractory to infection [7] , a phenomenon that is independent of the multiplicity of infection (data not shown), it is essential to restrict the analysis of MHC class-I and of RAE-1 expression to infected cells. This was achieved by twocolor cytofluorometric analysis of the expression of the viral ER-resident glycoprotein m164/gp36.5 (S.A.O.-K., manuscript in preparation) and MHC class-I glycoprotein L d (Fig. 2 , left column) [7] or of RAE-1 (Fig. 2 , right column), respectively. In accordance with the literature, L d expression was most strongly reduced in the presence of all three immunoevasins after infection with mCMV-WT.BAC and still significantly but less completely reduced in the selective presence of m152/gp40 after infection with mCMV-Dm04 + 06. This is in good accordance with the corresponding CTL sensitization data shown in Fig. 1b  (right panel) . Yet, since RAE-1 was found to be reduced simultaneously after infection with these two viruses (Fig. 2, right column) , the CTL sensitization data would be compatible also with NKG2D-RAE-1 interaction.
What clearly argues against epitope-independent CTL sensitization through NKG2D-RAE-1 interaction is the fact that uninfected cells as well as cells mock-infected with UV-inactivated virus failed to stimulate the CD8 T cells, although a significant proportion of them expressed NKG2D (Fig. 2) . In addition, as we have shown previously, IE1-CTLL completely failed in being sensitized by infected MEF derived from BALB/c-H-2 dm2 mice in which the IE1-epitope presenting MHC class-I molecule L d is not expressed due to a deletion in the MHC locus [7] . Another argument against a critical role for NKG2D-RAE-1-mediated sensitization of CD8 T cells is provided by recent data from Ann Hill's group demonstrating that blockade of this interaction with anti-NKG2D antibody had for some epitopes a detectable but altogether little impact on CTL activity [19] . This is in accordance with the current view that NKG2D-RAE-1 interaction does not independently lead to signaling in NKG2D-expressing T cells, but that NKG2D may act as a costimulatory molecule enhancing TCR-mediated, epitope-specific sensitization [20] . This applies then also to other NKG2D ligands, namely MULT-1 and H60 that are down-regulated by the virally-encoded proteins m145 and m155, respectively. Universal approach to test for epitope-specificity in vitro and in vivo Although we have now excluded a TCR-independent, epitope-unspecific activation of NKG2D-expressing CD8 T cells through interaction of NKG2D with its ligands expressed on target cells in vitro, the reasoning was complicated and was limited to a particular receptor-ligand interaction, not knowing whether other interactions might exist between CD8 T cells and mCMV-infected cells. Expression of putative virally-encoded ligands for such interactions appears to be plausible in the light of the fact that CMVs in general have a high coding capacity with many genes that are not essential for virus replication but may play a role in virus-host interaction.
For testing epitope-specificity of target cell recognition in vitro, and, more importantly, of protective antiviral function in vivo rigorously and unambiguously, we have chosen the universal genetic approach of selectively deleting an epitope by a point mutation of its C-terminal MHC anchor residue that binds to a hydrophobic pocket in the class-I molecule. This strategy has a reasonably good chance to selectively annul the recognition of the epitope of interest without affecting any other known as well as unkown interactions between CD8 T cells and infected target cells. The strategy is sketched in Fig. 3 for the case of the IE1 epitope. BAC mutagenesis was used to replace codon CTA with GCA leading to an amino acid replacement of leucine with alanine in mutant virus mCMV-IE1-L176A. For control and testing of unintended alterations in the genome, two revertant viruses were produced, namely mCMV-IE1-A176L by back-mutating codon GCA to CTA, as well as a revertant mCMV-IE1-A176L* in which a single nucleotide marker (like a single nucleotide polymorphism; SNP) is left in the wobble position of the Leu codon CTT [21, 22] .
As demonstrated in greater detail previously [21] , the L176A mutation did not interfere with any of the known regulatory functions of the IE1 protein but showed the intended immunological phenotype of preventing the recognition of infected target cells by IE1-specific CTL in vitro (Fig. 4a) , as well as the priming of an IE1 epitopespecific CD8 T cell response in vivo (Fig. 4b) . Thus, apparently, no other known or unknown receptor-ligand interaction between CD8 T cells and target cells was able to substitute for the specific recognition of L d -presented IE1 peptide by cognate TCRs. In a first approach, we used the preemptive therapy protocol (see also the review article by Holtappels et al. in this issue of MMI). Immunocompromised BALB/c recipients were infected with the WT-like virus revertant mCMV-IE1-A176L or with the epitope mutant mCMV-IE1-L176A and, on the same day, received graded numbers of IE1-CTLL. After 12 days, viral load in the lungs and spleen was determined by virus plaque assay, and infection of the liver was quantitated by immunohistology detecting intranuclear IE1 protein in infected liver cells (Fig. 5,  schema) . The data were unequivocal in that the transferred IE1 epitope-specific effector cells controlled the in vivo replication of the epitope-expressing revertant virus in a dose-dependent manner, whereas infection with the mutant virus progressed uninfluenced (Fig. 5, bottom) . In a second approach we asked if ex vivo TCR-sorted IE1-specific CD8-T M would behave someway differently (Fig. 6) . Except the known fact that CD8-T M are much more efficient than cells of a CTLL (see the review article by Holtappels et al. in this issue of MMI), the epitope-specificity was fully reproduced. For the liver, one might discuss a tendency towards control of the epitope mutant virus at higher cell numbers, but this did not reach statistical significance (comparison between 2,000 and 10,000 cells; P = 0.4; Wilcoxon-Mann Whitney rank sum test, twosided). For visualizing antiviral control by 10 4 transferred CD8-T M directly in liver tissue, a two-color immunohistology was performed that identified infected liver cellswhich in their majority are hepatocytes-by red staining of intranuclear IE protein and T cells by black staining of cell membrane-bound CD3e (Fig. 7) . Whereas many plaquelike foci of infection were found in livers infected with the epitope mutant virus (Fig. 7, panels a1 and a2) , infection with the revertant virus was confined to focal T cell infiltrates and largely controlled (Fig. 7, panels b1 and b2) .
Concluding remarks
In this work we have asked the question if the protective antiviral effect of CD8 T cells in the preemptive therapy of CMV infection is strictly epitope-specific, involving the recognition of MHC class-I-presented antigenic peptide by except that IE1 epitope-specific CD8-T M were transferred for preemptive immunotherapy. The CD8-T M were isolated from the spleens of latently infected BALB/c mice (at 3 months after infection with 10 5 PFU of mCMV-WT.Smith) by immunomagnetic purification of CD8 T cells followed by cytofluorometric sorting of cells expressing IE1 epitope-specific TCRs. For details of cell sorting, see reference [1] . Asterisks mark the individual mice used for the liver histology shown in Fig. 7 cognate TCRs, or if CD8 T cells can exert a beneficial function also by alternative receptor-ligand interactions. This question cannot be addressed in clinical research, but the murine model can provide ''proof of concept''. The answer given by the murine model was pretty clear: protection is strictly epitope-specific.
This finding has an additional implication. Besides alternative receptor-ligand interactions between CD8 T cells and infected tissue cells, an antiviral function of epitope-specific CD8 T cells that is unrelated to the recognition of the cognate epitope might have resulted from a ''degeneracy'' of epitope-specific TCRs (for classical and more recent reviews, see [23] [24] [25] [26] ). In essence, ''degeneracy'' means that TCRs are sufficiently flexible to tolerate mutations at the TCR contact site of cognate epitopes. TCRs may even recognize completely unrelated epitopes differing from the cognate epitope in amino acid sequence of the antigenic peptide as well as in the presenting MHC class-I molecule, most likely based on an analogous shape acquired by cognate and unrelated MHC-peptide complex. An early study identifying the TCR contact sites of the IE1 peptide has indeed revealed that replacements with alanine were critical for an IE1-specific monoclonal CTLL, whereas substitutions were tolerated by IE1-specific polyclonal CTLL ( [27] and M.J.R., unpublished data). Thus, our present study has shown that even for polyclonal IE1 epitope-specific CTLL as well as CD8-T M , cross-recognition of unrelated Another important aspect of our work concerns the somewhat astounding finding that focal T cell infiltrates, which develop in liver tissue infected with the IE1 peptideencoding revertant virus mCMV-IE1-A176L, are missing in liver tissue infected with the epitope mutant virus mCMV-IE1-L176A (Fig. 7) . So, the formation of T cell infiltrates is apparently epitope-specific; but how can T cells sense their cognate epitope from a distance to become recruited specifically to infected cells? In fact, it is more conceivable that T cells are attracted to the foci of infection by chemokines, as it was recently suggested from the finding that recruitment of antigen-specific T cells to the mCMV-infected liver involved the chemokines CXCL9 and CXCL10 as well as the expression of the corresponding chemokine receptor CXCR3 by the T cells [28] . Whether epitope-specificity of focal infiltrate formation relates to attraction of CD8 T cells or to local clonal expansion upon antigen encounter is an obvious question to be addressed next.
